Immune Checkpoint Inhibitors 2018
ICI Boston is the annual event that unites pioneering the drug developers who have successfully developed and implemented IO monotherapies and combinations.
Focused exclusively on identifying clinically effective combinations, validating patient selection biomarkers and assessing novel target pathways, ICI Boston is the only forum to provide a balanced and comprehensive insight into the development of the next generation of IO therapeutic strategies.
Join the leaders in the field and leave with key insights that will enable you to make the right decisions with your IO pipeline to lay the foundations for future success.
ICI Boston will enable you to: - Deliver robust and durable responses by gaining insights into rational immuno-oncology combination strategies - Differentiate yourself from the competition by understanding the true potential of the next generation of immunotherapies, including pioneering GITR, ICOS, VISTA and CD47 programs - Boost the response rate to checkpoint modulation by understanding the promise of oncolytic virotherapy, chemotherapy and radiotherapy in kick-starting anti-tumor immune responses - Enhance patient stratification by dissecting the utility of PD-L1 expression as a biomarker and examining the next generation of immune signature approaches - Ensure Commercial Success by examining how commercial partnerships and collaborations can be optimized and market share maximized in this rapidly evolving space - Bolster the holistic anti-tumour immune response by learning about the integral role NK cells, macrophages, Tregs, dendritic cells and many other cell types play.